INTELLIA ALERT: Bragar Eagel & Squire, P.C. is Investigating Intellia Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm GlobeNewswire May 23, 2025 NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Intellia Therapeutics, […]

(NASDAQ:GYRE), SAN DIEGO, May 22, 2025 (GLOBE NEWSWIRE) — Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biotechnology company focused on organ fibrosis, today announced the pricing of its previously announced underwritten public offering of 2,222,222 shares of its common stock at a public offering price of $9.00 per share. In addition, Gyre has granted

Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock GlobeNewswire May 23, 2025 SAN DIEGO, May 22, 2025 (GLOBE NEWSWIRE) — Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biotechnology company focused on organ fibrosis, today announced the pricing of its previously announced underwritten public offering of 2,222,222 shares of its common

(CNSX:AGN.CN),(OTC US:AGNPF),(Other OTC:AGNPF),(CNSX:AGN),(Boerse Frankfurt – Freiverkehr:AGW0.F), VANCOUVER, British Columbia, May 22, 2025 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare and clinical stage drug development company, is pleased to announce it has closed the acquisition to acquire 100% of the issued and outstanding shares

Algernon Closes NoBrainer Imaging Centers, Inc. Acquisition GlobeNewswire May 23, 2025 VANCOUVER, British Columbia, May 22, 2025 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare and clinical stage drug development company, is pleased to announce it has closed the acquisition to acquire 100% of

BOSTON, May 22, 2025 (GLOBE NEWSWIRE) — CECOCECO, a leading innovator in the lighting and display industry, is excited to announce its participation in the AIA Conference on Architecture & Design 2025, taking place from June 4-7 in Boston. At Booth #1119, CECOCECO will present the latest edition of ArtMorph–an innovative luminous wall panel that

CECOCECO to Unveil ArtMorph Innovation at AIA Conference on Architecture & Design 2025 GlobeNewswire May 23, 2025 BOSTON, May 22, 2025 (GLOBE NEWSWIRE) — CECOCECO, a leading innovator in the lighting and display industry, is excited to announce its participation in the AIA Conference on Architecture & Design 2025, taking place from June 4-7 in

Hidrovias International Finance S.à r.l., a private limited liability company (société à responsabilité limitée) incorporated in the Grand Duchy of Luxembourg, having its registered office at 17, Boulevard F.W. Raiffeisen, L-2411 Luxembourg, Grand Duchy of Luxembourg, and registered with the Luxembourg Register of Commerce and Companies (Registre de commerce et des sociétés, Luxembourg) under number

(HKSE:6855),(NasdaqGM:AAPG), ROCKVILLE, Md. and SUZHOU, China, May 22, 2025 (GLOBE NEWSWIRE) — Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, today announced that new clinical data from two ongoing investigational studies evaluating lisaftoclax in various blood cancers and alrizomadlin in solid tumors will be presented

Ascentage Pharma Announces Clinical Data of Lisaftoclax, Which Shows Therapeutic Potential in Venetoclax-Refractory Patients, Selected for Oral Report at ASCO 2025 GlobeNewswire May 23, 2025 ROCKVILLE, Md. and SUZHOU, China, May 22, 2025 (GLOBE NEWSWIRE) — Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, today